{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:56:51Z","timestamp":1753891011759,"version":"3.41.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Sweet syndrome (SS) is an uncommon inflammatory disease that involves painful skin, edematous, red papules, plaques, or nodules often accompanied by fever and leukocytosis. SS has three subtypes, including classical, malignant-tumor associated, and drug-induced SS (DISS). Patients with DISS have clear histories of recent drug exposure. The incidence of SS is high in hematological malignancy but rare in lymphomas. Glucocorticoid treatment is the recommended treatment for all subtypes of SS. This case study describes a male patient who had a history of sALCL(Systemic anaplastic large cell lymphoma) and was treated with multiple cycles of monoclonal-antibody (mAb) therapy. They also received the G-CSF injection at the site where skin lesions later developed. They met the diagnosis criteria for DISS, which was considered to be caused by the G-CSF injection. In addition, BV(Brentuximab vedotin) administration might predispose them to DISS. This case illustrates the first reported SS during the lymphoma treatment, with rare clinical presentations of local crater-like suppurative skin lesions. This case expands the available literature on SS and hematologic neoplasms and reminds clinicians to promptly recognize and diagnose SS to minimize patient morbidity and long-term sequelae.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1193808","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T04:28:29Z","timestamp":1685939309000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Atypical Sweet syndrome: skin sinus tracts in an acutely febrile patient after lymphoma treatment: a case report"],"prefix":"10.3389","volume":"14","author":[{"given":"Shi-Ying","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Li","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Kui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1964.tb14541.x","article-title":"An acute febrile neutrophilic dermatosis","volume":"76","author":"Sweet","year":"1964","journal-title":"Br J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1971.04000130083013","article-title":"Sweet\u2019s syndrome (acute febrile neutrophilic dermatosis)","volume":"103","author":"Shapiro","year":"1971","journal-title":"Rep case. Arch Dermatol"},{"key":"B3","article-title":"Diagnostic criteria for sweet\u2019s syndrome","volume":"37","author":"Su","year":"1986","journal-title":"Cutis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90080-8","article-title":"Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced sweet\u2019s syndrome","volume":"34","author":"Walker","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.critrevonc.2012.09.005","article-title":"Sweet\u2019s syndrome: a revisit for hematologists and oncologists","volume":"86","author":"Paydas","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2012.05744.x","article-title":"Pegfilgrastim-induced sweet\u2019s syndrome: a case report","volume":"53","author":"Machan","year":"2014","journal-title":"Int J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb08668.x","article-title":"Sweet\u2019s syndrome associated with G-CSF","volume":"85","author":"Payda\u015f","year":"1993","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.1874","article-title":"Insight into sweet\u2019s syndrome and associated-malignancy: a review of the current literature","volume":"42","author":"Raza","year":"2013","journal-title":"Int J Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0526","article-title":"Sweet\u2019s syndrome: a retrospective clinical, histopathological and immunohistochemical analysis of 11 cases","volume":"88","author":"Corazza","year":"2008","journal-title":"Acta Derm Venereol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(94)70215-2","article-title":"Sweet\u2019s syndrome (acute febrile neutrophilic dermatosis)","volume":"31","author":"von den Driesch","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1750-1172-2-34","article-title":"Sweet\u2019s syndrome\u2013a comprehensive review of an acute febrile neutrophilic dermatosis","volume":"2","author":"Cohen","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/0738-081X(93)90112-P","article-title":"Sweet\u2019s syndrome and cancer","volume":"11","author":"Cohen","year":"1993","journal-title":"Clin Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1997.tb03796.x","article-title":"Sweet\u2019s syndrome and malignancy in the U.K","volume":"137","author":"Bourke","year":"1997","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-010-1201-z","article-title":"EPONYM","volume":"169","author":"Kim","year":"2010","journal-title":"Sweet syndrome. Eur J Pediatr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01996.x","article-title":"Cutaneous manifestations of granulocyte colony-stimulating factor","volume":"31","author":"White","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.011","article-title":"Neutrophilic dermatosis complicating lenalidomide therapy","volume":"61","author":"Thieu","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04701.x","article-title":"Lymphocytic infiltrates as a presenting feature of sweet\u2019s syndrome with myelodysplasia and response to cyclophosphamide","volume":"146","author":"Evans","year":"2002","journal-title":"Br J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110523","article-title":"Azacitidine-associated sweet\u2019s syndrome","volume":"69","author":"Trickett","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21510","article-title":"Atypical presentations of sweet\u2019s syndrome in patients with MDS\/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors","volume":"84","author":"Alencar","year":"2009","journal-title":"Am J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2008.11.021","article-title":"[Bortezomib-induced acute neutrophilic dermatosis]","volume":"136","author":"Tanguy-Schmidt","year":"2009","journal-title":"Ann Dermatol Venereol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"ECR43","DOI":"10.3324\/%x","article-title":"Bortezomib-induced sweet\u2019s syndrome","volume":"90","author":"Van Regenmortel","year":"2005","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.3.368","article-title":"Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia","volume":"141","author":"Ayirookuzhi","year":"2005","journal-title":"Arch Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(03)00257-1","article-title":"Sweet\u2019s syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking imatinib mesylate","volume":"28","author":"Liu","year":"2004","journal-title":"Leuk Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.143","article-title":"Practical management of patients with chronic myeloid leukemia receiving imatinib","volume":"21","author":"Deininger","year":"2003","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31818866d8","article-title":"All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis","volume":"15","author":"Yu","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13074","article-title":"Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: a review","volume":"32","author":"Ravi","year":"2019","journal-title":"Dermatol Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2148-3","article-title":"Extensive toxic epidermal necrolysis following brentuximab vedotin administration","volume":"94","author":"Del Principe","year":"2015","journal-title":"Ann Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"van de Donk","year":"2012","journal-title":"MAbs"},{"key":"B33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/ddg.14197","article-title":"Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides)","volume":"19","author":"Pileri","year":"2021","journal-title":"J Dtsch Dermatol Ges."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01059","article-title":"Mechanisms of inflammation in neutrophil-mediated skin diseases","volume":"10","author":"Marzano","year":"2019","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00414","article-title":"Insights into the pathogenesis of sweet\u2019s syndrome","volume":"10","author":"Heath","year":"2019","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1193808\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T04:28:31Z","timestamp":1685939311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1193808\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2023.1193808"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1193808","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"article-number":"1193808"}}